Pilot Study on Effects of the Dialysis Mode on Posttranslational Modifications of Proteins

Not Applicable

Recruiting

• Conditions: N18.5; Chronic kidney disease, stage 5

• Registration Number: DRKS00010788
• Lead Sponsor: Dialysezentrum Elsenfeld

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-07-04
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

•Age = 18 years
•End-stage renal failure
•Chronic hemodialysis or hemodiafiltration treatment for more than three months
•Hematocrit above 30 %
•Stable anticoagulation and erythropoietin regimen
•No vascular access related problems (A/V-fistula or bi-flow catheter)
•No ongoing infection
•Signed informed consent form

Exclusion Criteria

•Inclusion criteria not met
•Known HIV or hepatitis B or C infection.
•Pregnancy
•Unstable clinical condition (e.g. cardiac or vascular instability)
•Life expectancy less than 12 months
•Known coagulation problems
•Patients participating in another study interfering with the planned trial

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum levels of posttranslationally modified proteins

Secondary Outcome Measures

Name	Time	Method
•Dialysis dose Kt/V<br>•Urea serum levels<br>•Protein catabolic rate<br>•Serum amino acids in blood and dialysate<br>•Small and middle molecular toxin removal<br>•Serum levels of protein-bound uremic toxins<br>•C-reactive protein<br>